{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastroenteropancreatic+Neuroendocrine+Tumor+%28GEP-NET%29", "query": { "condition": "Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 41, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastroenteropancreatic+Neuroendocrine+Tumor+%28GEP-NET%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-26T01:11:54.733Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04276597", "title": "Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Neuroendocrine Neoplasm", "Pheochromocytoma", "Paraganglioma", "Thymus Carcinoid", "Unknown Primary Tumors", "Neuroendocrine Tumors", "Neuroendocrine Skin Carcinoma", "Neuroendocrine Breast Tumor", "Neuroendocrine Carcinoma Metastatic", "Neuroendocrine Neoplasm of Ovary" ], "interventions": [ { "name": "177Lu-DOTATOC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Excel Diagnostics and Nuclear Oncology Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-03-04", "completion_date": "2021-07-15", "has_results": false, "last_update_posted_date": "2023-03-10", "last_synced_at": "2026-06-26T01:11:54.733Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04276597" }, { "nct_id": "NCT05636618", "title": "Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neuroendocrine Tumors Unresectable", "Neuroendocrine Tumor Metastatic", "Gastroenteropancreatic Neuroendocrine Tumor", "Bronchial Neuroendocrine Tumor", "Paraganglioma", "Pheochromocytoma", "Meningioma" ], "interventions": [ { "name": "[203Pb]VMT-α-NET", "type": "DRUG" }, { "name": "[212Pb]VMT-α-NET", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Perspective Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 300, "start_date": "2023-09-27", "completion_date": "2029-12-26", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-06-26T01:11:54.733Z", "location_count": 19, "location_summary": "Jacksonville, Florida • Miami, Florida • Chicago, Illinois + 16 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05636618" }, { "nct_id": "NCT05477576", "title": "Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "GEP-NET", "Gastroenteropancreatic Neuroendocrine Tumor", "Gastroenteropancreatic Neuroendocrine Tumor Disease", "Neuroendocrine Tumors", "Carcinoid", "Carcinoid Tumor", "Pancreatic NET" ], "interventions": [ { "name": "RYZ101", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" }, { "name": "Octreotide", "type": "DRUG" }, { "name": "Lanreotide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "RayzeBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 338, "start_date": "2022-03-24", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-06-26T01:11:54.733Z", "location_count": 32, "location_summary": "Phoenix, Arizona • Duarte, California • Irvine, California + 27 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05477576" }, { "nct_id": "NCT05064150", "title": "Neuroendocrine Tumors - Patient Reported Outcomes", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Neuroendocrine Tumors", "Gastroenteropancreatic Neuroendocrine Tumor", "Lung Neuroendocrine Neoplasm", "Neuroendocrine Carcinoma" ], "interventions": [], "intervention_types": [], "sponsor": "University of Iowa", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2539, "start_date": "2022-05-10", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-06-26T01:11:54.733Z", "location_count": 14, "location_summary": "Gainesville, Florida • Iowa City, Iowa • Kansas City, Kansas + 11 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05064150" }, { "nct_id": "NCT01010126", "title": "Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Hepatocellular Carcinoma", "Advanced Adult Hepatocellular Carcinoma", "Endometrial Serous Adenocarcinoma", "Localized Non-Resectable Adult Liver Carcinoma", "Lung Carcinoid Tumor", "Malignant Pancreatic Gastrinoma", "Malignant Pancreatic Glucagonoma", "Malignant Pancreatic Insulinoma", "Malignant Pancreatic Somatostatinoma", "Metastatic Digestive System Neuroendocrine Tumor G1", "Ovarian Carcinosarcoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Surface Papillary Adenocarcinoma", "Pancreatic Alpha Cell Adenoma", "Pancreatic Beta Cell Adenoma", "Pancreatic Delta Cell Adenoma", "Pancreatic G-Cell Adenoma", "Pancreatic Polypeptide Tumor", "Recurrent Adult Liver Carcinoma", "Recurrent Digestive System Neuroendocrine Tumor G1", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Pancreatic Neuroendocrine Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Recurrent Uterine Corpus Carcinoma", "Regional Digestive System Neuroendocrine Tumor G1", "Stage IIIA Fallopian Tube Cancer", "Stage IIIA Ovarian Cancer", "Stage IIIA Primary Peritoneal Cancer", "Stage IIIA Uterine Corpus Cancer", "Stage IIIB Fallopian Tube Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Primary Peritoneal Cancer", "Stage IIIB Uterine Corpus Cancer", "Stage IIIC Fallopian Tube Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Primary Peritoneal Cancer", "Stage IIIC Uterine Corpus Cancer", "Stage IV Fallopian Tube Cancer", "Stage IV Ovarian Cancer", "Stage IV Primary Peritoneal Cancer", "Stage IVA Uterine Corpus Cancer", "Stage IVB Uterine Corpus Cancer", "Uterine Carcinosarcoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Temsirolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 252, "start_date": "2009-09-08", "completion_date": "2017-03-13", "has_results": true, "last_update_posted_date": "2019-01-25", "last_synced_at": "2026-06-26T01:11:54.733Z", "location_count": 57, "location_summary": "Scottsdale, Arizona • Beverly Hills, California • Duarte, California + 44 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01010126" }, { "nct_id": "NCT03972488", "title": "Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastro-enteropancreatic Neuroendocrine Tumor" ], "interventions": [ { "name": "Lutathera", "type": "DRUG" }, { "name": "30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot)", "type": "DRUG" }, { "name": "2.5% Lys-Arg sterile amino acid solution", "type": "DRUG" }, { "name": "High dose 60 mg octreotide long-acting repeatable", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advanced Accelerator Applications", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 226, "start_date": "2020-01-08", "completion_date": "2027-10-29", "has_results": true, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-06-26T01:11:54.733Z", "location_count": 6, "location_summary": "New Haven, Connecticut • Tampa, Florida • Iowa City, Iowa + 3 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03972488" }, { "nct_id": "NCT03375320", "title": "Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Functioning Pancreatic Neuroendocrine Tumor", "Intermediate Grade Lung Neuroendocrine Neoplasm", "Locally Advanced Digestive System Neuroendocrine Neoplasm", "Locally Advanced Digestive System Neuroendocrine Tumor G1", "Locally Advanced Lung Neuroendocrine Neoplasm", "Locally Advanced Pancreatic Neuroendocrine Tumor", "Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm", "Low Grade Lung Neuroendocrine Neoplasm", "Lung Neuroendocrine Tumor", "Lung Neuroendocrine Tumor G2", "Metastatic Digestive System Neuroendocrine Neoplasm", "Metastatic Digestive System Neuroendocrine Tumor G1", "Metastatic Lung Neuroendocrine Neoplasm", "Metastatic Lung Neuroendocrine Tumor", "Metastatic Pancreatic Neuroendocrine Neoplasm", "Metastatic Pancreatic Neuroendocrine Tumor", "Metastatic Thymus Neuroendocrine Neoplasm", "Neuroendocrine Neoplasm", "Neuroendocrine Tumor", "Neuroendocrine Tumor G2", "Non-Functioning Pancreatic Neuroendocrine Tumor", "Pancreatic Serotonin-Producing Neuroendocrine Tumor", "Thymus Neuroendocrine Tumor", "Unresectable Digestive System Neuroendocrine Neoplasm", "Unresectable Digestive System Neuroendocrine Tumor G1", "Unresectable Lung Neuroendocrine Neoplasm", "Unresectable Pancreatic Neuroendocrine Neoplasm", "Unresectable Thymus Neuroendocrine Neoplasm" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Placebo Administration", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 298, "start_date": "2018-10-26", "completion_date": "2026-08-19", "has_results": true, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-06-26T01:11:54.733Z", "location_count": 433, "location_summary": "Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 290 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Kingman", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03375320" }, { "nct_id": "NCT05997056", "title": "Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroendocrine Tumors", "NET", "Pancreatic Neuroendocrine Tumor", "Gastrointestinal Neuroendocrine Tumor", "Pulmonary Neuroendocrine Tumor" ], "interventions": [ { "name": "nab-sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aadi Bioscience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2023-11-07", "completion_date": "2025-12-08", "has_results": false, "last_update_posted_date": "2024-07-16", "last_synced_at": "2026-06-26T01:11:54.733Z", "location_count": 4, "location_summary": "Newport Beach, California • Denver, Colorado • Dallas, Texas + 1 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Dallas", "state": "Texas" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05997056" }, { "nct_id": "NCT06253897", "title": "A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Gastro-enteropancreatic Neuroendocrine Tumor", "Acromegaly" ], "interventions": [], "intervention_types": [], "sponsor": "Ipsen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2024-05-29", "completion_date": "2024-12-06", "has_results": false, "last_update_posted_date": "2024-12-24", "last_synced_at": "2026-06-26T01:11:54.733Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT06253897" }, { "nct_id": "NCT03891784", "title": "Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Digestive System Neuroendocrine Neoplasm", "Digestive System Neuroendocrine Tumor", "Foregut Neuroendocrine Tumor", "Hindgut Neuroendocrine Tumor", "Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm", "Metastatic Digestive System Neuroendocrine Neoplasm", "Midgut Neuroendocrine Tumor", "Pancreatic Neuroendocrine Tumor", "Refractory Digestive System Neuroendocrine Neoplasm" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2019-10-31", "completion_date": "2026-07", "has_results": false, "last_update_posted_date": "2026-01-14", "last_synced_at": "2026-06-26T01:11:54.733Z", "location_count": 2, "location_summary": "Denver, Colorado • Seattle, Washington", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03891784" } ] }